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ttp://dx.doi.org/10.1016/j.ajpath.2013.02.010The a(1,3)-fucosyltransferases, types IV and VII (FUT4 and FUT7, respectively), are required for the
synthesis of functional selectin-type leukocyte adhesion molecule ligands. The selectins and their
ligands modulate leukocyte trafﬁcking, and P-selectin and its ligand, P-selectin glycoprotein ligand-1,
can modulate hemostasis and thrombosis. Regulation of thrombosis by FUT4 and/or FUT7 activity was
examined in mouse models of carotid artery thrombosis and collagen/epinephrine-induced throm-
boembolism. Mice lacking both FUT4 and FUT7 (Fut/ mice) had a shorter time to occlusive
thrombus formation in the injured carotid artery and a higher mortality due to collagen/epinephrine-
induced pulmonary thromboemboli. Mice lacking P-selectin or P-selectin glycoprotein ligand-1 did not
have a prothrombotic phenotype. Whole blood platelet aggregation was enhanced, and plasma
ﬁbrinogen content, clot weight, and clot strength were increased in Fut/ mice, and in vitro clot
lysis was reduced compared with wild type. Fut4/, but not Fut7/, mice had increased pulmonary
thromboembolism-induced mortality and decreased thromboemboli dissolution in vivo. These data
show that FUT4 and FUT7 activity regulates thrombosis in a P-selectine and P-selectin glycoprotein
ligand-1eindependent manner and suggest that FUT4 activity is important for thrombolysis.
(Am J Pathol 2013, 182: 2082e2093; http://dx.doi.org/10.1016/j.ajpath.2013.02.010)Supported by NIH grants HL090823 (J.W.H.) and HL073150 (D.T.E.).Abnormal post-translational glycosylation can change
protein structure, subcellular localization, stability, enzy-
matic activity, or immunogenic properties. Many proteins of
the coagulation system are heavily glycosylated,1 and vari-
ations in the presence or composition of their glycans are
known to modulate their function, thereby affecting hemo-
stasis and thrombosis.2e5 The fucosyltransferases are
a family of glycosyltransferases that catalyze the transfer of
L-fucose to an acceptor glycan on glycoproteins or glyco-
lipids. They are classiﬁed according to the location and
conﬁguration of the catalyzed bond between fucose and the
acceptor molecule. In humans, a(1,3/4)-fucosyltransferase
III (FUT3) catalyzes steps in the synthesis of carbohydrate
blood antigens, including the Lewis and Lewis-related
antigens (ie, Lea, Leb, Lex, LeY, sialyl-Lex, and sialyl-
Lea).6 Individuals who are Lewis negative or have an FUT3
polymorphism that reduces fucosyltransferase availability
(T59G) or enzymatic activity (T1067A and T202C) expe-
rience an increased incidence of atherothrombotic disease.7,8stigative Pathology.
.The FUT3 homologue in mice (Fut3) is a pseudogene,9
and the functional a(1,3)-fucosyltransferases, FUT4 and
FUT7, catalyze the synthesis of Lex and sialyl-Lex on
leukocytes and high endothelial venules. FUT7 plays
a predominant role, and FUT4 plays a subsidiary role, in the
synthesis of the sialyl-Lex tetrasaccharide moiety on selectin
ligands10 that is critical for ligand-binding activity.11,12
Mice with targeted mutations in both Fut4 and Fut7
(Fut/) have marked defects in selectin-dependent leuko-
cyte rolling in vitro and leukocyte recruitment in response to
acute inﬂammation and delayed-type hypersensitivity chal-
lenges.12,13 Mice lacking these FUTs are protected from
inﬂammation-induced pathological conditions, such as
atherosclerosis14,15 and renal ischemia-reperfusion injury.16
FUT7 expression is restricted primarily to leukocytes and
high endothelial venules, and it has precursor speciﬁcity for
sialyl-Lex synthesis. In contrast, FUT4 has a broader tissue
FUT4 and FUT7 Modulate Thrombosisexpression pattern and catalyzes the synthesis of sialyl-Lex,
Lex, and Ley moieties.6,17
Two functions of FUT4 and FUT7 suggest an interesting
potential role for these enzymes in modulating thrombosis
and hemostasis. First, FUT4 and FUT7 catalyze the
synthesis of functional P-selectin glycoprotein ligand-1
(PSGL-1; gene Selplg). Binding interactions of PSGL-1
with its receptor, P-selectin (gene Selp), contribute to
microvascular thrombosis by enhancing the generation of
tissue factorebearing microparticles and their recruitment
into a growing thrombus. Both actions enhance the local
generation of ﬁbrin to stabilize the growing thrombus.18,19
Second, human genetic association studies demonstrate
links between Lewis-related antigens and the risk of athe-
rothrombotic disease.7,8 We examined thrombosis and
hemostasis in Fut/ mice and found an unexpected pro-
thrombotic phenotype, enhanced platelet aggregation, and
a high plasma ﬁbrinogen concentration. Blood clot size and
strength were increased, and whole blood clots derived from
Fut/ mice were resistant to tissue-type plasminogen
activator-initiated thrombolysis. These results show that loss
of a(1,3)-fucosylation, mediated by FUT4 and FUT7,
results in enhanced thrombosis due to decreased thrombol-
ysis. They suggest that altered fucosylation of Lewis and
Lewis-related antigen structures modulates the thrombotic
phenotype in mice, and that altered fucosylation of these
structures may modulate the thrombotic phenotype in
humans with generalized fucosylation deﬁciencies20 or
speciﬁc a(1,3/4)-FUT polymorphisms.20,21
Materials and Methods
Materials
Endotoxin-free PBS, saline, and water were from Fisher
Scientiﬁc (Pittsburgh, PA). Rose bengal, prostaglandin E1
(PGE1), ADP, bovine serum albumin, and thrombin were
from Sigma-Aldrich (St. Louis, MO). The platelet aggre-
gation reagents, collagen and arachidonic acid (AA), were
from Chrono-Log (Havertown, PA). An enzyme-linked
immunosorbent assay (ELISA) speciﬁc for mouse ﬁbrin-
ogen was purchased from Kamiya Biomedical Company
(Seattle, WA) and used according to the manufacturer’s
protocol. Fibronectin-depleted and von Willebrand factore
depleted human ﬁbrinogen was purchased from Enzyme
Research Laboratories (South Bend, IN). Tissue plasmin-
ogen activator (t-PA) was from EMD Chemicals (La Jolla,
CA). Thrombin ﬂuorogenic substrate (Z-Gly-Gly-Arg-AMC)
and calibrator (a2-macroglobulin/thrombin) and tissue
factor were the generous gift of Dr. Alisa S. Wolberg
(University of North Carolina at Chapel Hill). Mice deﬁ-
cient in P-selectin or PSGL-1 were obtained from The
Jackson Laboratory (Bar Harbor, ME), and mice deﬁcient
in FUT4 and/or FUT7 were maintained in the laboratory of
one of the authors (J.W.H.). Experimental procedures and
animal husbandry conformed to the guidelines of theThe American Journal of Pathology - ajp.amjpathol.orgUniversity of North Carolina Institutional Animal Care and
Use Committee. Veterinary care was provided by the
University of North Carolina Department for Laboratory
Animal Medicine.
Rose Bengal Model of Carotid Thrombosis
Photochemical-induced carotid artery thrombosis was per-
formed as previously described.22 Mice were anesthetized
with 1.5% isoﬂurane in 2% oxygen. Body temperature was
determined with an anal probe and maintained at 37C using
a heating pad. A midline incision approximately 1.75 cm in
length was made on the anterior neck to expose the area of
the right proximal common carotid artery. The common
carotid artery was dissected free of surrounding tissues and
immersed in saline throughout the experiment. A Doppler
transonic ﬂow probe (Transonic Systems, Ithaca, NY) was
placed under the vessel to measure arterial blood ﬂow. A
540-nm green laser light beam of 1.5 mV (Melles Griot,
Carlsbad, CA) was continuously applied to the artery from
a distance of 6 cm. The photochemical, rose bengal (20 mg/
mL in PBS, 50 mg/kg ﬁnal concentration) was administered
via tail vein as a bolus over 5 seconds. The blood ﬂow was
monitored continuously until a stable occlusion occurred
(lasting a minimum of 60 seconds) or for 90 minutes if no
stable occlusion occurred.
Collagen/Epinephrine Model of Thromboembolism
Collagen/epinephrine (Col/Epi)einduced pulmonary throm-
boembolism was performed as previously described.23 Mice
were anesthetized i.p. with 25 mg/kg xylazine and 75 mg/kg
ketamine. Platelet agonist solution containing 75 mg/mL
collagen and 10 mg/mL epinephrine in PBS was freshly
prepared and administered as a bolus into the tail vein at 80
or 100 mL per 20 g body weight, depending on the experi-
ment. In some experiments, mice were made hyper-
ﬁbrinogenemic by infusion of human ﬁbrinogen (in 50 mL
PBS without calcium) 2 minutes before infusion of the Col/
Epi mixture. Mice were observed for up to 10 minutes. After
euthanasia, the lungs were insufﬂated with formalin via the
trachea to the end-expiration rib cage volume, removed,
ﬁxed insufﬂated in formalin for >48 hours, and parafﬁn
embedded. Coronal sections (5 mm thick) of the lungs were
cut just posterior to the lung hilum and stained with H&E.
The entire lung section was imaged in multiple, high-power,
nonoverlapping photomicrographs. Intra-arteriolar thrombi
(dimensions >50 mm and 25 mm in the perpendicular
direction) were counted using ImageJ image analysis soft-
ware version 1.35n (NIH, Bethesda, MD), and the number
of thrombi per cm2 was calculated.
Preparation of Washed Platelets
Platelets were isolated and washed according to published
methods24 at room temperature. Citrate-treated venous2083
Wang et alblood containing 5 mg PGE1 (1 mL) was layered onto
a 0.8-mL Accu-Prep lymphocyte gradient medium (Accu-
rate Chemical, Westbury, NY) and spun at 620  g for 20
minutes. The peripheral blood mononuclear cell and platelet
bandwere transferred to a clean polypropylene tube and diluted
with an equal volume of citrate-glucose buffer (13 mmol/L
sodium citrate, 30 mmol/L glucose, and 120 mmol/L NaCl,
pH 7.0) containing 5 mg/mL PGE1. The suspension was
centrifuged at 122  g for 10 minutes, and the platelets were
puriﬁed from the supernatant using a Sepharose (SigmaCL-2B-
300, Sigma, St. Louis, MO) column that was equilibrated with
Tyrode’s buffer (12 mmol/L NaHCO3, 138 mmol/L NaCl,
2.9 mmol/L KCl, 10 mmol/L HEPES, 5.5 mmol/L glucose,
1 mmol/LMgCl, 1 mmol/L CaCl2, and 1mg/mL bovine serum
albumin, pH 7.4). The efﬂuent fractions with high platelet
counts were collected.
Washed Platelet and Whole Blood Aggregation
Washed platelets were adjusted to 250  106/mL with
Tyrode’s buffer. Platelet aggregation was determined using
an optical aggregometer (Chrono-Log Optical Aggreg-
ometer 470; Chrono-Log). Platelet aggregation was induced
with 2 mg/mL ﬁnal concentration collagen or 0.5 mmol/L
ﬁnal concentration AA. Human ﬁbrinogen to a ﬁnal con-
centration of 15 mg/mL was added to the washed platelet
suspension to a ﬁnal concentration of 10 mmol/L before
ADP-induced aggregation.
Citrate-treated whole blood (500 mL) was diluted 1:1 with
prewarmed 500 mL HBSS (Gibco, Grand Island, NY) with
2 mmol/L CaCl2. Whole blood aggregation was determined
by impedance measurements using a Chronolog Lumi-
Aggregometer (model 700; Chrono-Log). Baseline was set
at 0%, and the impedance gain was set at 50%. Whole blood
aggregation was induced by addition of 3 mg/mL collagen,
10 mmol/L ADP, or 0.5 mmol/L AA (all ﬁnal concentrations).
Turbidometric Assay for Fibrin Polymerization
Wild-type (WT) platelet-poor plasma (PPP; 20 mL) was
spiked with 0, 13.5, 27, or 45 mg of human ﬁbrinogen in
PBS. Clot formation was triggered by the addition of 80 mL
HEPES buffered saline (20 mmol/L HEPES and
150 mmol/L NaCl, pH 7.4) containing a ﬁnal concentration
of 20 mmol/L CaCl2 and 0.1 U/mL thrombin. Clotting was
detected by turbidity at 405 nm in a SpectraMax Plus340
plate reader (Molecular Devices, Sunnyvale, CA).
Whole Blood TEG
The elasticity of clotting blood was evaluated using the TEG
Thromboelastograph Hemostasis analyzer (TEG 5000;
Haemonetics, Braintree, MA), according to the manufac-
turer’s protocol. Citrate-treated whole blood (360 mL) was
quickly mixed with a ﬁnal concentration of 20 mmol/L CaCl2
and immediately placed into untreated disposable cups for2084measurement. Clot strength is reﬂected by two parameters,
maximum amplitude (measured in millimeters) and shear
elastic modulus strength (measured in dyne/cm2). These
parameters are a direct function of the maximum dynamic
properties of ﬁbrin and platelet bonding and represent the
ultimate strength of the ﬁbrin clot.25
Blood Clotting and Clot Weight Determination
Citrate-treated venous whole blood was centrifuged at 100 
g for 15 minutes. The platelet-rich supernatant and peripheral
blood mononuclear cell/platelet layer were collected and
centrifuged at 100  g for 10 minutes to pellet peripheral
blood mononuclear cells. Platelet-rich plasma (PRP) was
collected and adjusted with PPP to a platelet concentration of
300  106/mL. PPP was obtained by centrifugation of the
remaining red blood cell layer (4000  g for 2 minutes).
Clotting of 300 mL PRP was initiated with addition of CaCl2
to a ﬁnal concentration of 20 mmol/L, and clot retraction
was allowed to proceed overnight at room temperature.
Clots were then rinsed with PBS, blotted to remove excess
ﬂuid, transferred to a preweighed tube, dried overnight, and
weighed.
To determine clot lysis, a ﬁnal concentration of 16 nmol/L
t-PA or saline was spiked into 300 mL citrate-treated whole
blood samples. Blood clotting was initiated with a ﬁnal
concentration of 20 mmol/L CaCl2. Clotting and clot re-
traction were allowed to proceed for 3 hours without
disturbance. The clots were then gently removed from the
tube wall if needed, and allowed to retract for an additional
2 hours, washed three times with PBS, dried, and weighed as
described.
Clot Lysis Assay
Citrate-treated venous whole blood (400 mL) in a poly-
propylene tube was spiked with 10 mg ﬂuorophore AF647-
labeled human ﬁbrinogen (hFG-AF647; Invitrogen, Grand
Island, NY) to approximately 1% of total plasma ﬁbrinogen,
and then with either 16 nmol/L t-PA (ﬁnal concentration) or
saline as control. Clotting was triggered by the addition of
a ﬁnal concentration of CaCl2 to 20 mmol/L and thrombin to
0.1 U/mL. Clots formed immediately, and clot retraction
was present after 20 minutes. At 40 minutes after clot
initiation, 900 mL HEPES buffered saline with 2 mmol/L
CaCl2 was added to the tube, and clots were gently peeled
away from tube wall to freely ﬂoat in the diluted serum. At
the indicated times, the tube was gently inverted several
times to equilibrate the concentration of the ﬁbrin degra-
dation products (FDPs) within the diluted serum; 110-mL
aliquots of the solution were centrifuged at 4000  g for
2 minutes to pellet cells. The ﬂuorescence intensity (675 nm)
of a 95-mL aliquot of the cell-free supernatant was determ-
ined. The concentration of hFDP-AF647 was determined
from an hFG-AF647 standard curve. The total amount of
hFDP-AF647 released from the clot at each time point wasajp.amjpathol.org - The American Journal of Pathology
FUT4 and FUT7 Modulate Thrombosiscalculated using the hFDP-AF647 concentrations and diluted
serum volumes. The percentage of clot lysis was calculated as
total hFDP-AF647/initially spiked hFG-AF647 (10 mg).
Statistical Analysis
Kaplan-Meier survival curve and most other statistical
analyses were performed with GraphPad Prism 3 software
(La Jolla, CA). Survival curves were analyzed using the log-
rank test. Thrombolysis data were analyzed by continued-
measures analysis of variance using StatView software
version 5.0.1 (Cary, NC). All other differences between
means of two genotypes were analyzed with the unpaired,
two-tailed Student’s t-test. Differences between groups were
considered signiﬁcant if P  0.05.
Results
Time to Artery Occlusion after Photochemical Injury Is
Shortened in Fut/ Mice
The thrombotic potential of Fut/ mice was determined
using photochemical-induced carotid artery thrombosis.
Thrombus formation in this model is dependent on both
platelet function and the coagulation cascade.26 Fut/ mice
had a 40% reduction in the time to occlusive thrombus
formation (Figure 1) ½time to occlusion (TTO)Z 19.5  9.6
minutes, compared with WT mice (TTO Z 34  9.7
minutes). The shortened TTO was not due to a functional
defect in FUT-catalyzed PSGL-1 activity because Selplg/
mice had a TTO similar to WT mice. In addition, Selp/
mice had a prolonged TTO compared with WT mice. These
results in mice lacking P-selectin or PSGL-1 are consistent
with previously documented prothrombotic roles for these
molecules.18,19 The data demonstrate that loss of fucosyla-
tion, mediated by FUT4 and FUT7, results in a pro-
thrombotic phenotype, and that the phenotype is dominant
to P-selectine and PSGL-1emediated mechanisms that
promote thrombosis.Figure 1 Time to occlusion after carotid artery injury is decreased in
Fut/ mice. The TTO was determined in Fut/, Selplg/, Selp/, and
corresponding WT (control) mice, all on a C57Bl/6 background, and
normalized to the average (31 minutes) WT value. Fut/ mice (n Z 12)
had a shortened TTO compared with WT (n Z 12). *P Z 0.002.
The American Journal of Pathology - ajp.amjpathol.orgPulmonary Thromboembolism Is Increased in
Fut/ Mice
The prothrombotic phenotype was conﬁrmed in Fut/mice
using a model of pulmonary thromboembolism induced by
infusion of a Col and Epi mixture. Mouse survival in this
model is dependent on the number, size, and stability of
thromboemboli formed as the result of the Col/Epi infusion.
Fut/ mice had a higher rate of mortality (P Z 0.003)
compared with WT mice in this model. Of WT mice, 83%
(10 of 12) survived the challenge (300 mg Col/48 mg Epi per
kg i.v.) compared with only 22% (2 of 9) of Fut/ mice
(Figure 2A). The thrombotic potential of PSGL-1edeﬁcient
mice was also examined using this model. However, at this
dose, WT mice had a high rate of survival. Therefore, we
used a higher Col/Epi dose (375 mg Col/60 mg Epi per kg i.v.)
that resulted in a higher WT mortality rate to detect possible
protection afforded by loss of PSGL-1. At this higher dose, 3
of 10WTmice survived, and 4 of 10 PSGL-1edeﬁcient mice
survived (P Z 0.27) (Figure 2B). Histological sections of
lung tissue were analyzed for the presence of thromboemboli
(Table 1 and Figures 2C and 2D). Fut/ mice had a higher
count of thromboemboli in lung tissue compared with WT
mice, consistent with the higher mortality of these mice. No
difference was found in thromboemboli count between WT
and PSGL-1edeﬁcient mice.
Whole Blood Platelet Aggregation Is Enhanced in
Fut/ Mice
Platelets are a central contributor to both arterial and
collagen/epinephrine-induced thrombosis. Circulating
platelet counts were not different between WT (776  118 
106/mL, nZ 13) and Fut/ (852 153 106/mL, nZ 13)
(P Z 0.18) mice. Platelet aggregation was assessed using
impedance aggregometry in whole blood (Table 2). These
studies showed a consistently shortened lag time and
increased rate of aggregation in Fut/ whole blood triggered
by 10 mmol/L of the platelet agonist, ADP, or 3 mg/mL
collagen, compared with WT whole blood. The aggregation
amplitude for these agonists was not signiﬁcantly altered.
Enhanced aggregation in Fut/ mice was most pronounced
when triggered by 0.5 mmol/L AA. The lag time was short-
ened by 52%, the rate was increased 2.1-fold, and the
amplitude was increased 3.3-fold. Washed platelet aggrega-
tion was performed with the same agonists (Table 3), in an
absorbance-based aggregometry assay, to determine whether
the enhanced aggregation is the result of factors intrinsic or
extrinsic to the platelet. No genotype-dependent differences in
washed platelet aggregation were observed.
Prothrombin Time, Partial Thromboplastin Time, and
Thrombin Generation Are Not Altered in Fut/ Mice
We examined whether fucosyltransferase deﬁciency altered
traditional measures of coagulation pathway activation,2085
Figure 2 Pulmonary thromboembolism-induced
mortality is higher in Fut/ mice. A: Kaplan-Meier
survival curves for thromboembolus-induced
mortality after treatment with 300 mg/kg Col and
48 mg/kg Epi. Mortality was signiﬁcantly higher in
Fut/ mice (7 of 9) compared with WT mice (2 of
12). PZ 0.003. B: Mortality of Selplg/ mice (6 of
10) was similar to mortality for WT mice (7 of 10)
after treatment with 375 mg/kg Col and 60 mg/kg
Epi. PZ 0.5. C: Representative low-power image of
H&E-stained Fut/ whole lung section used to
determine the thrombus count. D: Representative
high-power images of WT (left panel) or Fut/
(right panel) lung sections showing the formed
thrombi (arrows).
Wang et alincluding prothrombin time (PT) and activated partial
thromboplastin time. There was no detectable difference in
the plasma PT or activated partial thromboplastin time
between Fut/ and WT mice (Figure 3, A and B). Cali-
brated automated thrombography detected increased
thrombin generation in a prothrombotic state mimicked by
the addition of exogenous prothrombin (Figure 3C) and
was, therefore, used to assess the prothombotic state of
mouse plasma ex vivo. No difference in thrombin generation
was detected between Fut/ and WT plasma (Figure 3D),
as determined by the lag time to thrombin generation, time
to peak thrombin generation, peak height, or endogenous
thrombin potential (area under the thrombin generation
curve).
Plasma Fibrinogen Concentration and Clot Strength Are
Increased in Fut/ Mice
Plasma ﬁbrinogen concentration (Figure 4A) was deter-
mined using a mouse ﬁbrinogen-speciﬁc ELISA. Fut/
plasma had a signiﬁcantly higher concentration of ﬁbrin-
ogen (5.8  0.4 mg/mL; 30% increase) compared with WTTable 1 Genotype-Dependent Quantiﬁcation of Pulmonary
Thromboemboli
Dose (mg/kg BW) Genotype Thrombi/cm2 P value
Col 300/Epi 48 WT 110  35 (n Z 9) 0.007
Fut/ 251  30 (n Z 9)
Col 375/Epi 60 WT 341  45 (n Z 9) 0.27
Psgl-1/ 279  33 (n Z 10)
Data are given as means  SD.
BW, body weight.
2086(4.5  0.3 mg/mL). The ﬁbrinogen level in Selplg/
plasma (4.7  0.6 mg/mL) was not different from WT,
indicating that the increase is independent of PSGL-1
activity. A turbidometric measure of plasma ﬁbrin poly-
merization (Figure 4B) showed that a 30% increase in
ﬁbrinogen concentration, achieved in vitro by addition of
puriﬁed human ﬁbrinogen, results in signiﬁcantly more
ﬁbrin polymerization that could contribute to enhanced
thrombus stabilization. Consistent with these data, clots that
formed in Fut/ PRP resulted in higher clot dry weight
compared with WT (2.2  0.6 versus 1.3  0.2 mg; from
300-mL PRP with platelet counts at 300  106/mL)
(Figure 4C).
High ﬁbrinogen concentrations facilitate formation of
a densely packed ﬁbrin network, and ﬁbrin network structure
can determine clot mechanical properties.27 Therefore, we
tested the mechanical properties of whole blood clots from
Fut/ or WT mice using thromboelastography (TEG).
Compared with WT mice, clots from Fut/ whole blood
were stronger and more elastic (Figure 4, C, D, and E), as
measured by the TEG parameters of maximum amplitude and
shear elastic modulus strength. These results are consistent
with previous reports that elevated ﬁbrinogen,27 in combi-
nation with enhanced platelet activation (Table 2), results in
increased mechanical clot strength.
FUT4 Mediates Enhanced Pulmonary Thromboembolism
Independent of Hyperﬁbrinogenemia
We tested whether the hyperﬁbrinogenemia observed in
Fut/ mice enhances Col/Epi-induced mortality. Pulmo-
nary thromboembolism was induced in WT mice after
infusion with PBS or human ﬁbrinogen to obtain a plasmaajp.amjpathol.org - The American Journal of Pathology
Table 2 Whole Blood Platelet Aggregation
Variable
Whole blood
ADP (10 mmol/L; n Z 8) Col (3 mg/mL; n Z 8) AA (0.5 mmol/L; n Z 12)
WT Fut/ WT Fut/ WT Fut/
LT (seconds) 27.0  0.6 22.2  0.5* 88.1  3.2 78.0  2.1* 39.8  6.2 20.8  1.3*
Slope 16.4  1.0 21.4  0.9* 12.0  0.8 14.8  0.7* 9.1  2.2 19.3  0.8*
MA (%) 12.1  0.6 13.0  0.7 14.1  0.6 13.5  0.6 3.0  0.9 9.8  0.7*
All values represent means  SD.
*P < 0.05 vs the corresponding WT.
AA, arachidonic acid; Col, collagen; LT, lag time; MA, maximum amplitude.
FUT4 and FUT7 Modulate Thrombosisﬁbrinogen concentration equivalent to 150% of the WT
concentration. The mortality rate was not higher in the
hyperﬁbrinogenemic mice compared with the PBS-treated
mice (Figure 5A). Mice deﬁcient in FUT4 alone have
slightly reduced plasma ﬁbrinogen compared with WT
(4.02  0.4 versus 4.5  0.3 mg/mL; nZ 6 per group; PZ
0.07), yet have a high rate of mortality (Figure 5B)
comparable to the Fut/ mice. In addition, mice deﬁcient
in FUT7 alone have a high plasma ﬁbrinogen concentration
compared with WT (5.6  0.7 versus 4.5  0.3 mg/mL;
nZ 6 per group; PZ 0.01), but have a low mortality rate,
similar to WT mice (Figure 5C). These data suggest that the
30% higher ﬁbrinogen concentration in Fut/ mice is not
the primary cause of the high mortality in these mice and
that increased thromboembolism-induced mortality is asso-
ciated with loss of FUT4 activity.
Reduced Fibrinolysis in Fut/ Mice
Experiments tested whether ﬁbrinolysis is altered in Fut/
mice. Endothelial cellederived tissue-type plasminogen acti-
vator (t-PA) and urokinase-type plasminogen activator incor-
porate into the forming clot and convert plasminogen to
plasmin, which lyses ﬁbrin into soluble FDPs. We ﬁrst
demonstrated the role of the coagulation system in the patho-
genesis of pulmonary thromboembolism induced by the
platelet-activating agents, collagen and epinephrine. Pulmo-
nary thromboembolism was induced in control WT mice
or WT mice i.v. treated with either 100 mg low-molecular-
weight heparin (Lovenox; Sanoﬁ US, Bridgewater, NJ) or 4
or 8 mg/kg t-PA (human t-PA; Activase; EMD Chemicals,Table 3 Washed Platelet Aggregation
Variable
Washed platelets
ADP (10 mmol/L; n Z 3)* Col (2 m
WT Fut/ WT
LT (seconds) 14.0  2.1 14.0  2.5 95.2  7
Slope 67.7  3.4 70.0  2.5 59.0  1
MA (%) 77.7  0.7 82.3  3.3 81.8  1
All values represent means  SD.
*Human ﬁbrinogen (15 mg/mL ﬁnal concentration) was added for ADP-stimula
AA, arachidonic acid; Col, collagen; LT, lag time; MA, maximum amplitude.
The American Journal of Pathology - ajp.amjpathol.orgLa Jolla, CA). Treatment with low-molecular-weight heparin
or the higher dose of t-PA protected the mice from pulmonary
thromboembolismeinduced mortality (Figure 6A). These data
conﬁrm that the coagulation cascade plays a critical role in
collagen/epinephrine-induced thromboembolism, likely by
stabilizing formed platelet-rich microthrombi, and suggest
that thrombolysis may be an important protective mechanism
in this model.
The temporal appearance and resolution of pulmonary
thromboemboli were determined to assess genotype-dependent
alterations in thrombolysis in this model. The number of
thromboemboli present in the lungs was not different between
WT andFut/mice (WT, 399 22;Fut/, 381 29; nZ 6
per group;PZ 0.6) (Figure 6B) when counted early (1minute)
after Col/Epi infusion. In contrast, when thromboemboli were
counted late (at death or 10 minutes) after treatment, there were
far fewer thromboemboli in lungs of WT mice (110 35/cm2,
nZ 9) or Fut7/ mice (129  28/cm2, nZ 10; PZ 0.67),
most of which survived, compared with the Fut/ (251 30/
cm2, nZ 9; PZ 0.007) or Fut4/ (250  33/cm2, nZ 11;
PZ 0.009) mice, most of which died. These temporal changes
in thromboemboli counts indicate that fucosyltransferase deﬁ-
ciency does not signiﬁcantly alter initial thrombus formation,
but that subsequent thrombus dissolution (thrombolysis) is
reduced in Fut/ or Fut4/ mice that have high mortality
rates. For standardization, lungs from mice that died prema-
turely were harvested at the 10-minute time point, theoretically
allowing for changes in thrombus size or number in the interim.
However,without hemodynamic forces or circulation to deliver
or remove plasma or thrombus components, such changes
should be limited.g/mL; n Z 5) AA (0.5 mmol/L; n Z 5)
Fut/ WT Fut/
.7 110  11.3 35.0  0.8 36.6  1.1
.8 58.7  1.5 71.1  5.6 67.4  1.5
.2 84.4  0.5 73.5  6.2 74.8  1.3
ted washed platelet aggregation.
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Figure 3 Prothrombin time (PT), partial thromboplastin time (PTT), and thrombin generation in Fut/mice. A and B: The time to initial ﬁbrin formation via
the extrinsic (A) or intrinsic (B) pathway was not altered in Fut/ mice. C: Calibrated automated thrombography detects increased thrombin generation in WT
mouse PPP spiked with prothrombin. D: Thrombin generation and activity were not different betweenWT and Fut/mice, respectively, as determined by lag time
(4.1 1.4 versus 3.8 0.8 seconds; nZ 5 per group, PZ 0.73), maximum thrombin generation peak (21.8 3.1 versus 21.5 1 nmol/L; PZ 0.93), time to
maximum thrombin generation (9.4  1.7 versus 8.7  1.4 seconds; PZ 0.44), or endogenous thrombin potential (326  84 versus 269  20; PZ 0.18).
Wang et alFibrinolysis of whole blood clot was directly evaluated by
mixing 16 nmol/L exogenous t-PA into whole blood before
clot formation was initiated with CaCl2 and excess thrombin
(ﬁnal, 1 U/mL). This procedure was used because a 400-fold
greater concentration of t-PA is required to achieve the same
degree of lysis if the t-PA is added subsequent to clot
formation.28 Fluorescence-labeled human ﬁbrinogen
(ﬁbrinogen-AF647; 10 mg), which is approximately 1% of
total ﬁbrinogen, was added to whole blood before coagu-
lation initiation, and the extent of clot lysis was determined
by measuring the percentage of total ﬁbrinogen-AF647
released from the clot as FDP-AF647. Minimal clot lysis
occurred in the absence of exogenous t-PA (Figure 7A)
(t-PA, 0 nmol/L), and there was no difference in lysis
between genotypes. In contrast, signiﬁcant lysis occurred
with 16 nmol/L t-PA, but the lysis of Fut/ whole blood
clot was signiﬁcantly reduced at each time point by an
average of 46% compared with WT clot (Figure 7A). In
a separate experiment, the dry weight of whole blood clot
was measured after clotting in the presence or absence of 16
nmol/L t-PA. Consistent with the clot lysis data, Fut/
whole blood clot retained its clot mass better than WT
whole blood clot. Clot lysis with 16 nmol/L t-PA reduced
WT clot dry weight by 38% from the weight without t-PA
(Figure 7B). In contrast, t-PA only reduced Fut/ dry clot
weight by 9%. Together, these data demonstrate that clots
from Fut/ mice are resistant to lysis, and provide addi-
tional evidence that fucosyltransferase-dependent mod-
ulation of thrombolysis contributes to the observed
prothrombotic phenotype.
Discussion
Selectin-dependent processes can modulate thrombosis and
hemostasis by several recently reviewed mechanisms.18,19
PSGL-1 or glycoprotein Ib expressed on platelets binds
endothelial P-selectin to enable platelet rolling and recruit-
ment to a forming thrombus. Binding of membrane-bound2088or soluble P-selectin to leukocyte PSGL-1 induces expres-
sion of tissue factor on monocytes and the formation of
procoagulant leukocyte microparticles that can subsequently
be recruited to the forming thrombus. Mice harboring tar-
geted mutations of Fut4 and Fut7 lack functional selectin
ligand activity11,12 and, therefore, lack P-selectin/PSGL-1
binding interactions. Together, these ﬁndings suggested
a potential role for FUT4 and FUT7 in modulating selectin-
dependent thrombotic processes. They predict that Fut/
mice would have an anti-thrombotic phenotype because
they lack the fucosylation of PSGL-1 that is necessary for
P-selectin binding. In contrast to the prediction, our ﬁndings
show that these mice have a shortened time to thrombotic
occlusion after photochemical-induced carotid artery injury.
This model was initially chosen to examine large-artery
thrombosis instead of microvascular thrombosis, in which
P-selectin interactions with PSGL-1 are known to enhance
thrombosis, and because of the limited vascular injury
compared with the transmural injury caused by ferric
chloride treatment. The thrombus in this model of carotid
artery injury is platelet rich, and this model has been used to
study the role of platelets and platelet inhibitors in arterial
thrombosis.29 In addition, coagulation-modifying factors,
such as plasminogen activator inhibitor-1 and vitronectin,
also modulate thrombosis in this model.22,30 The pro-
thrombotic phenotype was conﬁrmed in a second throm-
bosis model by showing that Fut/ mice have increased
mortality in a model of pulmonary thromboembolism. The
role of platelets in this model is evident in the model’s
dependence on the platelet-activating agents, epinephrine
and collagen, and modulation of platelet function in this
model alters thromboembolus formation.31,32 However,
coagulation factors are also critical in this model.33 In
addition, P-selectin/PSGL-1emediated processes, including
microparticle formation, are known to be important in
venous thrombus formation and resolution.34 Thus,
thrombus formation in both models involves platelet acti-
vation and aggregation, as well as activation of theajp.amjpathol.org - The American Journal of Pathology
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Figure 4 Plasma ﬁbrinogen concentration, clot size, and clot strength are increased in Fut/ mice. A: The ﬁbrinogen concentration in Fut/ plasma
(5.83  0.4 mg/mL, nZ 6) is 30% higher than that in WT plasma (4.47  0.6 mg/mL, nZ 6). B: Fibrin polymerization was enhanced in WT mouse PPP spiked
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(50% hFG). Polymerization curves are representative of three independent experiments. C: Platelet-rich plasma (PRP) clot size is increased in Fut/ plasma
compared with WT plasma (2.2  0.2 versus 1.3  0.1 mg dry weight; nZ 7 per genotype). D and E: Thromboelastogram parameters showed that an Fut/
clot had an increased maximum amplitude (75  0.8 versus 69  0.9 mm; nZ 7 per genotype; D) and increased clot ﬁrmness (shear elastic modulus strength,
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FUT4 and FUT7 Modulate Thrombosiscoagulation cascade and ﬁbrin formation, to stabilize the
thrombus.
The plasma ﬁbrinogen concentration in Fut/ mice was
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during aggregation, forming the ﬁbrin network, and enabling
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Figure 6 Thrombolysis protects mice from collagen/epinephrine-
induced pulmonary thromboembolism. A: Thromboembolism was trig-
gered in WT mice treated as indicated. All mice that received PBS or low
dose t-PA (4 mg/kg) had respiratory distress, and 50% succumbed to the
treatment. In contrast, mice treated with low-molecular-weight heparin or
8 mg/kg t-PA showed no signs of pulmonary distress, and 100% survived.
B: At 1 minute after treatment with Col/Epi, all mice were alive and the
number of thrombi/cm2 lung was similar between WT and Fut/ mice. At
the ﬁnal time point (death or 10 minutes), most WT and Fut7/ mice
survived, and had reduced thrombi counts. In contrast, most Fut/ and
Fut4/ mice died and had high thrombi counts. All mice below the dotted
line survived, except one Fut4/ mouse, and all mice above the line died.
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Figure 7 A whole blood clot from Fut/ mice is resistant to
t-PAemediated lysis. A: Clot lysis was assessed by the release of AF647-
labeled ﬁbrin degradation products (FDP-AF647). The WT and Fut/
curves are signiﬁcantly different (WT, n Z 4; Fut/, n Z 5; P Z 0.03).
The percentage lysis ratio (WT to Fut/) at each time point is indicated
below the graph. B: Clot size in the absence and presence of t-PA. The
addition of 16 nmol/L t-PA reduced WT (nZ 8) dry clot weight by 38%. In
contrast, Fut/ clot weight (n Z 7) was only reduced by 9% by the
addition of t-PA. The t-PAetreated Fut/ whole blood clot size was
signiﬁcantly heavier than the t-PAetreated WT clots. *P Z 0.005.
Wang et alplatelet-dependent clot retraction.27,35 Machlus et al27
showed a decreased time to carotid artery thrombosis in
mice with human ﬁbrinogen-induced hyperﬁbrinogenemia
(170% of WT) using the ferric chlorideeinduced injury
model. Our data in the photochemical-induced injury model
showed a shortened time to arterial thrombosis in Fut/
mice with less severe hyperﬁbrinogenemia (130% of WT).
However, the time to occlusion was not shortened in Fut7/
mice with hyperﬁbrinogenemia of a similar magnitude
(125% of WT), suggesting that hyperﬁbrinogenemia is not
the primary mechanism for enhanced arterial thrombosis in
the Fut/ mice.
In our pulmonary thromboembolism studies, hyper-
ﬁbrinogenemia did not correlate with thromboembolism-
induced mortality. Mortality was enhanced in mice lacking
both FUT4 and FUT7 that were hyperﬁbrinogenemic
(130% of WT) and in mice lacking only FUT4 that had2090normal to slightly low plasma ﬁbrinogen, but not in mice
lacking FUT7 that were hyperﬁbrinogenemic (125% of
WT). In addition, mortality was not increased in WT mice
made hyperﬁbrinogenemic (150% of WT) by treatment with
ﬁbrinogen. These data show that mortality in this model is
largely independent of the plasma ﬁbrinogen concentration
if it is near or higher than the concentration in WT mice. A
possible alternative mechanism to account for a high
mortality rate is decreased thrombolysis. Support for this
mechanism is provided by the in vitro data showing that
t-PAemediated Fut/ ﬁbrin clot degradation is reduced by
45% compared with WT (Figure 7) and the in vivo data
showing that thromboembolus dissolution during the
experiment was reduced in Fut/ and Fut4/ mice,
resulting in higher mortality compared with WT and Fut7/
mice (Figure 6B).
Moderate enhancement of Fut/ whole blood aggrega-
tion was measured in response to several agonists, but was
most pronounced in response to AA. These data suggest that
the mechanism of enhancement, not speciﬁcally determinedajp.amjpathol.org - The American Journal of Pathology
FUT4 and FUT7 Modulate Thrombosisby our experiments, is independent of pathways speciﬁc to
a given agonist/receptor. Aggregation of washed Fut/
platelets was not altered compared with WT. This ﬁnding
may be the result of the wash protocol (ie, treatment with
PGE1 or the removal of plasma components, including
ﬁbrinogen) or the experimental methods (impedance versus
absorbance), or may suggest that the enhancement is not due
to a mechanism intrinsic to the platelet. The enhanced whole
blood platelet aggregation in Fut/ mice was not associ-
ated with more thromboemboli in the lungs of Fut/ mice
early after collagen-epinephrine infusion. These data
suggest that the moderate enhancement of platelet aggre-
gation also does not lead to increased thromboemboli
formation in Fut4/ mice. However, activated platelets
contribute to processes that stabilize a thrombus, once
formed. They enhance thrombin generation through the
release of coagulation factors and the assembly of thrombin-
generating molecular complexes on their surface.36,37
Activated platelets also decrease ﬁbrinolysis by releasing
plasminogen activator inhibitor-138,39 from a granules, by
enhancing clot retraction,40,41 and by increasing platelet
release and activation of thrombin-activatable ﬁbrinolysis
inhibitor.41 Therefore, it is possible that the increased
platelet function in Fut/ mice contributed to the pro-
thrombotic phenotype of these mice by helping to stabilize
the formed thrombi.
Many coagulation factors are heavily glycosylated,1 and
variation in the glycosylation pattern can signiﬁcantly alter
the function of a factor. Glycosylation affects the kinetics of
ﬁbrinogen polymerization,42 clearance of von Willebrand
factor43 and antithrombin,3 isoform activity of factor V,2,44
post-translational folding of factor VII,45 activation of
factor IX,46 activity of plasminogen activator inhibitor-1 and
protein S4, and biochemical properties of thrombin-
activatable ﬁbrinolysis inhibitor.47 Our data show that
glycan a(1,3)-fucosylation modulates the thrombotic process
by mechanisms that are independent of P-selectin/PSGL-
1emediated events and dependent on FUT4 activity, sug-
gesting that altered fucosylation of a coagulation factor may
account for the phenotype.
Fut/ mice have a marked deﬁciency in selectin ligand
activity that severely limits selectin-dependent trafﬁcking of
neutrophils and monocytes, and homing of naive T lym-
phocytes.11,12 In addition, loss of P-selectinedependent
interactions has been shown to reduce microvascular throm-
bosis.18,19 These two phenotypes would be expected to limit
atherogenesis in mice deﬁcient in apolipoprotein E (ApoE)
and FUT7 (ApoE//Fut7/). However, Fut/ mice have
a marked neutrophilia and a moderate monocytosis,12 and the
studies reported herein show a dominate prothrombotic
phenotype in these mice. In contrast to the ﬁrst two pheno-
types, the latter two would be expected to exacerbate athero-
genesis in ApoE//Fut7/ mice. Previous studies showed
that atherosclerotic lesion size in ApoE/ mice is limited by
loss of FUT7 activity.14 Together, these ﬁndings suggest that
the anti-inﬂammatory effects afforded by reduced leukocyteThe American Journal of Pathology - ajp.amjpathol.orgtrafﬁcking and lymphocyte homing are the dominant pheno-
type with respect to atherogenesis in these mice.
Previous human studies have identiﬁed single-nucleotide
polymorphisms that decrease FUT3 activity and lead to
increased formation of the Le(ab) antigen, which is
associated with atherothrombotic disease.7,8 Synthesis of
Lea and Leb by FUT3 requires a(1,4)-fucosylation of a type
I precursor, but FUT3 also has a(1,3) activity and can use
type II precursors similar to FUT4.48 In contrast, FUT4 is
not known to have a(1,4)-fucosyltransferase activity. Both
FUT3 and FUT4 are expressed in a fairly broad and over-
lapping tissue distribution, including in the liver and
epithelial tissues. However, FUT3 is a pseudogene in the
mouse. Tissue expression of FUT7 is limited and does not
overlap with FUT3. Given the prothrombotic phenotype
associated with loss of FUT4 in mice, it is interesting to
consider whether the atherothrombotic disease associated
with decreased FUT3 activity in humans is due to loss of
FUT3-mediated a(1,3)-fucosyltransferase activity that is
redundant with FUT4 activity. Additional studies are war-
ranted to better understand the mechanism(s) by which
FUT4 and FUT7 contribute to homeostasis of the coagula-
tion system.Acknowledgments
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